# Mesenchymal Stem Cells for the Treatment of Various Chronic and Acute Conditions

Study · id `cardio:ct-nct04684602` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04684602](<https://clinicaltrials.gov/study/NCT04684602>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04684602

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 5000 participants.

## Technical summary

Registry record NCT04684602. Non-randomized; no masking; primary purpose treatment. Start 2020-07-09 (actual); primary completion 2030-07-09 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Phase 1/2
- Enrolled: 5000 participants (planned count; ClinicalTrials.gov record NCT04684602, source copy `cardio:ctgov-nct04684602-2022-04-29`, retrieved 2026-10-26)
- Started: 2020-07-09 (actual) (ClinicalTrials.gov record NCT04684602, source copy `cardio:ctgov-nct04684602-2022-04-29`, retrieved 2026-10-26)
- Primary completion: 2030-07-09 (anticipated) (ClinicalTrials.gov record NCT04684602, source copy `cardio:ctgov-nct04684602-2022-04-29`, retrieved 2026-10-26)
- Completion: 2030-12-09 (anticipated) (ClinicalTrials.gov record NCT04684602, source copy `cardio:ctgov-nct04684602-2022-04-29`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT04684602, source copy `cardio:ctgov-nct04684602-2022-04-29`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04684602-2022-04-29`, retrieved 2026-10-26)

## The registry's words

- Brief title: Mesenchymal Stem Cells for the Treatment of Various Chronic and Acute Conditions
- Condition: Autoimmune Diseases
- Condition: Cardiovascular Disorders
- Condition: Diabetes Complications
- Condition: Integumentary Disease
- Condition: Musculoskeletal Disorders
- Condition: Neurodegenerative Disorders
- Condition: Neurologic Disorders
- Condition: Pulmonary Disorders
- Condition: Sexual Dysfunction
- Condition: Urologic Disorders
- Condition: Viral Illness
- Intervention (Biological): PrimePro™/ PrimeMSK™
- Lead sponsor: Thomas Advanced Medical LLC
- Lead sponsor class: INDUSTRY
- Collaborator: HeartStem Institute
- Collaborator class: UNKNOWN
- Collaborator: NuStem
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Cardiomyopathy (heart muscle disease) (`cardio:cardiomyopathy`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)

## Provenance

Content hash: 3024a772a7ebfdd4019789e8db57050a6fd249946d5e83a55299e9c3eb53acde
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
